73 related articles for article (PubMed ID: 38674302)
21. Total neoadjuvant therapy for rectal cancer: a guide for surgeons.
Johnson GGRJ; Park J; Helewa RM; Goldenberg BA; Nashed M; Hyun E
Can J Surg; 2023; 66(2):E196-E201. PubMed ID: 37085291
[TBL] [Abstract][Full Text] [Related]
22. The evolution of rectal cancer treatment: the journey to total neoadjuvant therapy and organ preservation.
Iv AA; Koprowski MA; Nabavizadeh N; Tsikitis VL
Ann Gastroenterol; 2022; 35(3):226-233. PubMed ID: 35599927
[TBL] [Abstract][Full Text] [Related]
23. Screening and prevention of colorectal cancer.
Kanth P; Inadomi JM
BMJ; 2021 Sep; 374():n1855. PubMed ID: 34526356
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
25. Factors Associated with the Quality of Life of Patients with Cancer Undergoing Radiotherapy.
Seol KH; Bong SH; Kang DH; Kim JW
Psychiatry Investig; 2021 Jan; 18(1):80-87. PubMed ID: 33460533
[TBL] [Abstract][Full Text] [Related]
26. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis.
Kasi A; Abbasi S; Handa S; Al-Rajabi R; Saeed A; Baranda J; Sun W
JAMA Netw Open; 2020 Dec; 3(12):e2030097. PubMed ID: 33326026
[TBL] [Abstract][Full Text] [Related]
27. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
28. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.
Schmoll HJ; Stein A; Van Cutsem E; Price T; Hofheinz RD; Nordlinger B; Daisne JF; Janssens J; Brenner B; Reinel H; Hollerbach S; Caca K; Fauth F; Hannig CV; Zalcberg J; Tebbutt N; Mauer ME; Marreaud S; Lutz MP; Haustermans K
J Clin Oncol; 2021 Jan; 39(1):17-29. PubMed ID: 33001764
[TBL] [Abstract][Full Text] [Related]
29. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
Zhang Y; Yan L; Wu Y; Xu M; Liu X; Guan G
BMC Cancer; 2020 Sep; 20(1):854. PubMed ID: 32891131
[TBL] [Abstract][Full Text] [Related]
30. Quality of Life After Radiotherapy for Rectal and Anal Cancer.
Neibart SS; Manne SL; Jabbour SK
Curr Colorectal Cancer Rep; 2020 Feb; 16(1):1-10. PubMed ID: 32632345
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant radiotherapy for rectal cancer management.
Feeney G; Sehgal R; Sheehan M; Hogan A; Regan M; Joyce M; Kerin M
World J Gastroenterol; 2019 Sep; 25(33):4850-4869. PubMed ID: 31543678
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).
Hattori N; Nakayama G; Uehara K; Aiba T; Ishigure K; Sakamoto E; Tojima Y; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Nagino M; Kodera Y
Int J Clin Oncol; 2020 Jan; 25(1):118-125. PubMed ID: 31542847
[TBL] [Abstract][Full Text] [Related]
33. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes.
Petrelli F; Trevisan F; Cabiddu M; Sgroi G; Bruschieri L; Rausa E; Ghidini M; Turati L
Ann Surg; 2020 Mar; 271(3):440-448. PubMed ID: 31318794
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
Lieu CH; Golemis EA; Serebriiskii IG; Newberg J; Hemmerich A; Connelly C; Messersmith WA; Eng C; Eckhardt SG; Frampton G; Cooke M; Meyer JE
Clin Cancer Res; 2019 Oct; 25(19):5852-5858. PubMed ID: 31243121
[TBL] [Abstract][Full Text] [Related]
35. Role of clinical oncology pharmacist in determination of pharmaceutical care needs in patients with colorectal cancer.
Tezcan S; İzzettin FV; Sancar M; Turhal NS; Yumuk PF
Eur J Hosp Pharm; 2018 Mar; 25(e1):e17-e20. PubMed ID: 31157061
[TBL] [Abstract][Full Text] [Related]
36. A review of sex-related differences in colorectal cancer incidence, screening uptake, routes to diagnosis, cancer stage and survival in the UK.
White A; Ironmonger L; Steele RJC; Ormiston-Smith N; Crawford C; Seims A
BMC Cancer; 2018 Sep; 18(1):906. PubMed ID: 30236083
[TBL] [Abstract][Full Text] [Related]
37. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
Sclafani F; Brown G; Cunningham D; Wotherspoon A; Mendes LST; Balyasnikova S; Evans J; Peckitt C; Begum R; Tait D; Tabernero J; Glimelius B; Roselló S; Thomas J; Oates J; Chau I
Br J Cancer; 2017 Nov; 117(10):1478-1485. PubMed ID: 28934761
[TBL] [Abstract][Full Text] [Related]
38. The relationship between cancer patient's fear of recurrence and chemotherapy: A systematic review and meta-analysis.
Yang Y; Wen Y; Bedi C; Humphris G
J Psychosom Res; 2017 Jul; 98():55-63. PubMed ID: 28554373
[TBL] [Abstract][Full Text] [Related]
39. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis.
de Jong EA; ten Berge JC; Dwarkasing RS; Rijkers AP; van Eijck CH
Surgery; 2016 Mar; 159(3):688-99. PubMed ID: 26619929
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
